Literature DB >> 24375503

Rho GTPases and cancer.

Hui Li1, Karine Peyrollier, Gülcan Kilic, Cord Brakebusch.   

Abstract

Rho GTPases are a family of small GTPases, which play an important role in the regulation of the actin cytoskeleton. Not surprisingly, Rho GTPases are crucial for cell migration and therefore highly important for cancer cell invasion and the formation of metastases. In addition, Rho GTPases are involved in growth and survival of tumor cells, in the interaction of tumor cells with their environment, and they are vital for the cancer supporting functions of the tumor stroma. Recent research has significantly improved our understanding of the regulation of Rho GTPase activity, the specificity of Rho GTPases, and their function in tumor stem cells and tumor stroma. This review summarizes these novel findings and tries to define challenging questions for future research.
© 2013 International Union of Biochemistry and Molecular Biology.

Entities:  

Keywords:  Rho GTPases; cancer

Mesh:

Substances:

Year:  2013        PMID: 24375503     DOI: 10.1002/biof.1155

Source DB:  PubMed          Journal:  Biofactors        ISSN: 0951-6433            Impact factor:   6.113


  33 in total

1.  The R-Enantiomer of Ketorolac Delays Mammary Tumor Development in Mouse Mammary Tumor Virus-Polyoma Middle T Antigen (MMTV-PyMT) Mice.

Authors:  Amanda S Peretti; Dayna Dominguez; Martha M Grimes; Helen J Hathaway; Eric R Prossnitz; Melanie R Rivera; Angela Wandinger-Ness; Donna F Kusewitt; Laurie G Hudson
Journal:  Am J Pathol       Date:  2017-11-21       Impact factor: 4.307

2.  MicroRNA-31 inhibits RhoA-mediated tumor invasion and chemotherapy resistance in MKN-45 gastric adenocarcinoma cells.

Authors:  Alireza Korourian; Raheleh Roudi; Ahmad Shariftabrizi; Zahra Madjd
Journal:  Exp Biol Med (Maywood)       Date:  2017-08-24

3.  Elevated levels of epithelial cell transforming sequence 2 predicts poor prognosis for prostate cancer.

Authors:  Zhenghui Guo; Xianju Chen; Tao Du; Dingjun Zhu; Yiming Lai; Wen Dong; Wanhua Wu; Chunhao Lin; Leyuan Liu; Hai Huang
Journal:  Med Oncol       Date:  2016-12-23       Impact factor: 3.064

4.  Ablation of RhoA impairs Th17 cell differentiation and alleviates house dust mite-triggered allergic airway inflammation.

Authors:  Jun-Qi Yang; Khalid W Kalim; Yuan Li; Yi Zheng; Fukun Guo
Journal:  J Leukoc Biol       Date:  2019-07-01       Impact factor: 4.962

5.  Rational targeting Cdc42 restrains Th2 cell differentiation and prevents allergic airway inflammation.

Authors:  Jun-Qi Yang; Khalid W Kalim; Yuan Li; Xin Duan; Phuong Nguyen; Gurjit K Khurana Hershey; John Kroner; Brandy Ruff; Li Zhang; Nathan Salomonis; Mark Rochman; Ting Wen; Yi Zheng; Fukun Guo
Journal:  Clin Exp Allergy       Date:  2018-11-13       Impact factor: 5.018

Review 6.  Rho GTPases in cancer: friend or foe?

Authors:  Julius H Svensmark; Cord Brakebusch
Journal:  Oncogene       Date:  2019-08-19       Impact factor: 9.867

Review 7.  Profiling invasiveness in head and neck cancer: recent contributions of genomic and transcriptomic approaches.

Authors:  Lluís Nisa; Daniel Matthias Aebersold; Roland Giger; Marco Domenico Caversaccio; Urs Borner; Michaela Medová; Yitzhak Zimmer
Journal:  Cancers (Basel)       Date:  2015-03-31       Impact factor: 6.639

8.  Cancer Invasion: Patterns and Mechanisms.

Authors:  N V Krakhmal; M V Zavyalova; E V Denisov; S V Vtorushin; V M Perelmuter
Journal:  Acta Naturae       Date:  2015 Apr-Jun       Impact factor: 1.845

9.  Spatial and temporal control of Rho GTPase functions.

Authors:  Konstadinos Moissoglu; Martin Alexander Schwartz
Journal:  Cell Logist       Date:  2014-05-01

10.  Dissecting the epigenomic dynamics of human fetal germ cell development at single-cell resolution.

Authors:  Li Li; Lin Li; Qingqing Li; Xixi Liu; Xinyi Ma; Jun Yong; Shuai Gao; Xinglong Wu; Yuan Wei; Xiaoye Wang; Wei Wang; Rong Li; Jie Yan; Xiaohui Zhu; Lu Wen; Jie Qiao; Liying Yan; Fuchou Tang
Journal:  Cell Res       Date:  2020-09-03       Impact factor: 46.297

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.